Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Two Formulations of MK-1167 in Healthy Participants
NCT07334860Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-1167 in Alzheimer's disease (AD) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Curve from Time 0 to Infinity up to 21 days, Maximum Plasma Concentration up to 21 days and 1 more. Started Feb 2026; status: completed.
02
Drugs
MK-1167
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07334860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334860.